The FDA granted breakthrough device designation to the Haystack MRD test, which uses ctDNA to detect residual or recurrent ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad’s ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings ...

The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for identifying patients with minimal ...

MRD testing is crucial for high-risk MM patients, aiding in early detection and treatment decisions, despite logistical and insurance barriers. Physicians primarily use MRD to monitor remission ...

The FDA has granted breakthrough device designation to the Haystack MRD test, a circulating tumor DNA (ctDNA) test, for use ...

The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for patients with stage 2 colorectal ...

Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity.

The US Food and Drug Administration (FDA) has granted breakthrough device designation for Quest Diagnostics’ Haystack minimal ...

In this video, Sandra Mazzoni, DO, discusses the use of minimal residual disease, or MRD, testing in multiple myeloma. “There’s a lot of hot topics right now in myeloma in general,” Mazzoni ...

Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR Tracer ...

1 Minimal Residual Disease Testing Market Report Introduction 2PR Newswire LAS VEGAS, Aug. 20, 2025 The demand for minimal residual disease testing is increasing mainly due to the higher ...